Leukocyte immunoglobulin-like receptors (LILRs) are inhibitory, stimulatory or soluble receptors encoded within the leukocyte receptor complex. Some LILRs are extensively polymorphic, and exhibit evidence for balancing selection and association with disease susceptibility. LILRA2 (LIR7/ILT1) is an activating receptor highly expressed in inflammatory tissues, and is involved in granulocyte and macrophage activation. In this study, we examined the association of LILRA2 and adjacently located LILRA1 with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and microscopic polyangiitis (MPA). Polymorphism screening detected a LILRA2 SNP (rs2241524 G4A) that disrupts splice acceptor site of intron 6. Case-control association studies on 273 Japanese SLE, 296 RA, 50 MPA and 284 healthy individuals revealed increase of genotype A/A in SLE (12.1%, odds ratio (OR) 1.82, 95% confidence interval (CI) 1.02-3.24, P ¼ 0.041) and in MPA (16.0%, OR 2.52, 95% CI 1.07-5.96, P ¼ 0.049) compared with healthy individuals (7.0%). The risk allele caused an activation of a cryptic splice acceptor site that would lead to a novel LILRA2 isoform lacking three amino acids in the linker region (D419-421). Flow cytometry indicated that this isoform was expressed on the surface of monocytes. These findings suggested that LILRA2 D419-421 isoform encoded by the splice site SNP may play a role in SLE and MPA.
Introduction
The family of leukocyte immunoglobulin (Ig)-like receptor (LILR, also known as LIR, immunoglobulin-like transcript (ILT), CD85 or monocyte/macrophage inhibitory receptor) consists of 13 member genes including two pseudogenes (LILRP1 and LILRP2). [1] [2] [3] LILRs can be divided into three groups. The first group (LILRA1, -A2, -A4, -A5 and -A6) delivers positive signals by pairing with the Fc receptor common g-chain (FcRg), which contains an immunoreceptor tyrosine-based activation motif. The second (LILRB1, -B2, -B3, -B4 and -B5) contains 2-4 immunoreceptor tyrosine-based inhibitory motif-like sequences within the cytoplasmic region and inhibits cell activation by recruiting Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) or SH2 domain-containing inositol phosphatase (SHIP). The third group, LILRA3 and LILRA5s, is thought to be secreted as soluble receptors.
The LILR gene family is located in the leukocyte receptor complex on human chromosome 19q13. 4 , which also contains a number of closely related Ig-like receptor genes such as killer cell Ig-like receptors (KIRs) and FCAR. [4] [5] [6] This region has been suggested to be one of the candidate susceptibility regions for systemic lupus erythematosus (SLE) by linkage analyses. 7, 8 In the syntenic region of mice, proximal end of chromosome 7, activating and inhibitory paired Ig-like receptor A and B (Pira, Pirb), orthologs of human LILR genes, are located. 9, 10 Mice lacking Pirb showed impaired maturation of dendritic cells (DCs) and increased Th2 responses. 11 Furthermore, it was reported that both PIR-A and -B proteins bind to various mouse MHC class I molecules, and Pirb-deficient mice showed exacerbated graft-versus-host disease. 12 These observations suggest that LILRs may be critically involved in the regulation of immune system in various aspects.
LILRA2 is an activation receptor broadly expressed on hematopoietic cells such as monocytes, macrophages, myeloid DCs, granulocytes and subset of NK cells. 13, 14 It is reported that the expression of LILRA2 was significantly upregulated in lesions of lepromatous leprosy patients. 15 The synovium from patients with rheumatoid arthritis (RA) showed extensive expression of inhibitory LILRB2 and activating LILRA2 on macrophages and neutrophils. 16 Although some of the LILRs and KIRs bind to HLA class I molecules or UL-18, a HLA class I homolog expressed by human cytomegalovirus, 17, 18 ligands for LILRA2 have not been identified.
LILRA2 is implicated in the activation of eosinophils, 19 basophils 20 and macrophages. 21 On the other hand, it is reported that activation of LILRA2 suppresses innate host defense mechanisms by shifting monocyte production from IL-12 toward IL-10 and blocking toll-like receptor (TLR)-mediated antimicrobial activity. 15 In mice, PIR-A, an ortholog of LILRA2, has been shown to be an essential costimulatory receptor for osteoclast differentiation. 22 RA is a chronic rheumatic disease that leads to progressive joint destruction. It is characterized by synovial proliferation and autoimmune features such as production of rheumatoid factor and anticyclic citrullinated peptide antibodies. SLE is a prototypic systemic autoimmune disease characterized by multisystem organ involvement, high level of antinuclear autoantibody and immune complex deposition. Microscopic polyangiitis (MPA) is a rare disease characterized by necrotizing vasculitis of small-to-medium-size vessels, and the patients often present with severe manifestations such as rapidly progressive glomerulonephritis and pulmonary hemorrhage. Most of the patients with MPA exhibit antineutrophil cytoplasmic antibodies. The etiology of these rheumatic diseases is poorly understood, but probably involves interactions among environmental and genetic factors.
We have been interested in the role of diversity of immunoregulatory molecules in the genetic background of human rheumatic diseases, and Ig-like receptor superfamily has been one of our major targets. [23] [24] [25] With respect to the LILR family, we thus far reported that LILRB1 was highly polymorphic and associated with susceptibility to RA. 26 Extensive polymorphism appears to be a feature of LILR family, and evidence for balancing selection has been found for another activating member of LILR family, LILRA3.
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As described above, human chromosome 19q13 has been suggested to be one of the candidate loci for susceptibility to SLE. LILRA2 is functionally implicated in immunoregulation, granulocyte activation and potentially osteoclast differentiation. These constitute crucial pathways of the rheumatic diseases such as SLE, RA and MPA. In this study, we examined whether LILRA2 polymorphisms are associated with susceptibility to human SLE, RA and MPA.
Results
Association of a LILRA2 splice acceptor site polymorphism with susceptibility to SLE Polymorphism screening of all exons and promoter region (approximately 2 kb) of LILRA2 gene was performed on genomic DNA from 12 Japanese SLE, 12 RA patients and 16 Japanese controls by direct sequencing. Six single nucleotide polymorphisms (SNPs) and three rare variations (only one heterozygote among all individuals screened) were detected ( Figure 1 ).
Among the detected SNPs, rs2241524 (IVS6-1 G4A) located at intron 6-exon 7 junction disrupts the consensus splicing acceptor motif and was thought to be functionally relevant. Case-control association study demonstrated that A/A genotype was increased in SLE (odds ratio (OR) 1.82, 95% confidence interval (CI) 1.02-3.24, P ¼ 0.041) as compared with controls ( Table 1 ). The control genotype was not deviated from HardyWeinberg equilibrium. The genotype frequency in the controls was similar to that of Japanese sample set in the HapMap database (http:/ /www.hapmap.org/index.html.en) (G/G 51.2%, G/A 44.2%, A/A 4.7%). Actually, the increase in the A/A genotype in the patients was even more striking when compared with the HapMap samples, because the frequency of A/A was slightly lower in the HapMap samples than in our controls.
Lack of association of other polymorphisms in the linkage disequilibrium block encompassing rs2241524 We next investigated whether this association might be caused by linkage disequilibrium (LD) with other causative variations. According to the HapMap database, the LD block encompassing rs2241524 contains the entire LILRA2 locus and 5 0 portion of adjacently located LILRA1 (LIR6) locus, and no other gene was present. We carried out polymorphism screening of LILRA1 including the promoter region (approximately 1.4 kb). Twenty-four LILRA1 SNPs, including 11 novel SNPs, were identified ( Figure 1 ). Among these, 5 0 portion 19 SNPs (from promoter region to intron 7) were found to constitute two major haplotypes, tentatively designated LILRA1.PC01 and LILRA1.PC02 (PC stands for promoter and coding region) (Table 2a, Figure 1 ). The frequency of LILRA1.PC01 was 74.2% and that of LILRA1.PC02 was 22.6% in the parents of 31 Japanese healthy samples used for haplotype determination, whereas c.490C4T (H164Y) and c.581C4G (S194W) seemed to be infrequent variations (o1%).
We next examined association of potentially functional LILRA2 polymorphisms in the promoter region (rs3760856, rs28384501, rs28384502) and also LILRA1.PC haplotype with SLE. rs28384501 and rs28384502 were only 2 bp apart and in absolute LD in the controls used in this study. Other polymorphic sites were also in significant, but not absolute LD (Figure 1 ). None of these polymorphisms was significantly associated with SLE, nor haplotypes were formed by these polymorphic sites (Tables 2b and c) . Thus, we concluded that LILRA2 rs2241524 itself was most likely to be responsible for the association with SLE.
Association of a LILRA2 rs2241524 with susceptibility to MPA We next examined whether LILRA2 rs2241524 was associated with RA and MPA. Association of A/A genotype was observed in MPA (OR 2.52, 95% CI 1.07-5.96, P ¼ 0.049), but not in RA ( Table 1) .
Effects of the LILRA2 splice acceptor SNP on the transcript Because rs2241524 disrupts the consensus splicing acceptor motif of LILRA2 intron 6, we investigated the difference in the sequence of mRNA generated from each allele. To detect a small difference in mRNA size, RT-PCR was performed using primers placed on exon 6 and 7, and the products were analyzed by capillary gel electrophoresis. This analysis revealed a clear difference in size of the mRNA from each allele (Figure 2a) .
By sequencing, the longer product derived from G allele was found to be conventional LILRA2 transcript, whereas the band derived from A allele was found to encode a 9-nucleotide shorter novel transcript. This isoform was caused by the activation of a cryptic splice acceptor site 9-nt downstream to the original site ( Figure 2b ). The usage of the alternative splice acceptor site was absolutely dependent on the genotype, because only a single product, long and short, was amplified from G/G and A/A genotypes, respectively ( Figure 2a ).
Such alternative splicing was presumed to result in the deletion of three amino acids (Ala-Ser-Leu at position 419-421) in the linker region between Ig-like domains and transmembrane region of LILRA2 protein ( Figure 2c ). This isoform was termed as D419-421 isoform.
Cell surface expression of LILRA2 isoforms
We next examined whether the D419-421 isoform was expressed at the protein level. Because peripheral blood monocytes are known to express LILRA2, two-color flow cytometric analysis was performed using monoclonal antibodies (mAbs) against LILRA2 (anti-ILT1 mAb135) 14 and CD14. This analysis was performed using two healthy donors with G/G and two with A/A genotype.
LILRA2 was detected on the monocytes both from G/G and A/A donors ( Figure 3 ). Because individuals with A/A genotype exclusively use the cryptic splice site, detection of LILRA2 protein on the cell surface in Table 1 Frequencies of LILRA2 splice acceptor site polymorphism in Japanese patients with SLE, RA, MPA and healthy controls Numbering starts at the ATG translation initiation codon. rs number for each SNP is shown in Figure 1 .
b Association was shown under the recessive model, because the association of rs2241524 was detected under this model. Other models also failed to detect significant association.
c LILRA2 rs28384501 A4T is in absolute LD with rs28384502 A4T.
LILRA2 splice site SNP in SLE and vasculitis K Mamegano et al these donors indicated that LILRA2 D419-421 protein isoform was expressed on the cell surface. The intensity of LILRA2 staining was similar in both genotypes.
Discussion
In this study, we reported evidence that suggests association of an intron 6-exon 7 junction SNP of LILRA2 with susceptibility to SLE and MPA. This SNP disrupts the consensus splice acceptor motif, and results in the activation of a cryptic splice acceptor site located at 9-nt downstream to the original site, leading to the in-frame deletion of three amino acids in the linker region of LILRA2 protein (D419-421). The usage of the alternative splice acceptor site was entirely dependent on the genotype; thus, G allele always gives rise to the common isoform, while A allele exclusively produces D419-421 
The presence of LILRA2 protein on the surface of monocytes from A/A genotype, therefore, indicates that the D419-421 isoform is expressed on the cell surface at the protein level.
The mechanism of association of LILRA2 remains speculative. The signal intensity of LILRA2 in the flow cytometric analysis did not substantially differ between individuals with G/G and A/A genotypes, suggesting that D419-421 did not affect expression level or gross structure of the protein. It would be more likely that the deletion of the three amino acids alters affinity of the LILRA2 to as yet unknown ligands and/or FcRg chain, which is the signaling component of LILRA2.
It has been shown that LILRA2 modifies TLR signaling in monocytes and macrophages. 15 A number of recent observations demonstrate the crucial role of type I interferon in SLE. 28 Because TLR signals are important inducers of type I interferons, association with SLE could be explained if D419-421 isoform may promote stronger TLR signals.
In MPA, activation of neutrophils and macrophages plays an important role in the pathogenesis. 29 Several lines of evidence demonstrated the role of LILRA2 in the activation of myeloid cells and macrophages. 14, [19] [20] [21] Thus, stronger signals via D419-421 isoform might explain its association with MPA.
LILRA2 was also suggested to play a role in the regulation of Th1/Th2 balance. 15 As Th1 cytokines have been implicated both in SLE and MPA, 29, 30 Th1/Th2 imbalance caused by D419-421 isoform could be another potential mechanism of association. The association of LILRA2 was in a recessive manner, which was responsible for the deviation of this genotype from the HardyWeinberg equilibrium in SLE. Such recessive association could suggest a loss-of-function mechanism. If LILRA2 D419-421 isoform is associated with reduced induction of Th2 cytokines and leads to Th1-dominant environment, the recessive mode of genetic association might be explained.
The power to detect susceptibility genes in this study was not sufficient in the case of MPA due to its rarity. Assuming that prevalence of SLE, RA and MPA is 0.001, 0.01 and 0.0001, respectively, and the population frequency of the risk allele is 0.25, the power to detect susceptibility genes with the genotype relative risk of 1.5 at the significance level of 0.05 is calculated to be 0.87, 0.88 and 0.42, respectively. 31 In addition, because the P-values are marginal, genotyping error could lead to false positive association. However, such a possibility is unlikely; the genotyping was performed by direct sequencing and the genotyping error rate should be negligible. Furthermore, the frequency of the A/A genotype in the Japanese samples on the HapMap database was even lower compared with our controls, which lend support to the association of this genotype with SLE and MPA. Nevertheless, in order to confirm this association, independent studies in Japanese and other populations should be performed in the future. Another limitation of this study was a bias in the sex ratio between cases and controls. However, because the frequency of each SNP was not significantly different between males and females, the results were essentially identical when they are adjusted for the sex ratio.
In conclusion, this study suggested that the splice acceptor site polymorphism of LILRA2 leading to the deletion of three amino acids was associated with susceptibility to SLE and MPA in Japanese. Taken together with the previous observations from our laboratory, LILR family members are rich in functional polymorphisms, and may be involved in the genetic background of immune response diversity in the human population as well as in the susceptibility to multiple immune system disorders. 36 Since those definitions do not provide diagnostic or classification criteria, and ACR classification criteria do not include MPA, the MPA was diagnosed in accord with the Japanese criteria proposed by the Research Committee in 1998. 32 This study was approved by the research ethics review committees of the University of Tokyo, University of Tsukuba, Juntendo University and each participating institute.
Patients and methods

Patients and controls
Genomic DNA from patients and healthy individuals was purified from peripheral blood using the QIAamp blood Kit (Qiagen, Hilden, Germany).
Polymorphism screening and genotyping of LILRA2 Polymorphisms of all exons and promoter region of LILRA2 gene were screened using PCR-direct sequencing method. Genomic DNA samples from 16 healthy individuals, 12 SLE and 12 RA patients were used for screening. The primers were designed according to the genomic DNA sequence of human LILRA2 (NCBI accession no. NC_000019). The primers used for polymorphism screening and the regions screened are shown in Table 3 and Figure 1 . Because the genomic DNA sequences of LILR family genes are highly homologous, nested PCR was used to achieve specific amplification of LILRA2. LILRA2 gene was divided into three fragments. Two fragments of 5 0 region (2040 bp upstream from the translation start site to 355 bp downstream of the 3 0 end of exon 6) were amplified as overlapping fragments by means of long PCR (nested first PCR) using two primer sets. A fragment encompassing the entire exon 7 was separately amplified. Because intron 6 extends approximately 11 kb, a systematic polymorphism screening was not performed.
As for nested first PCR, one primer set was placed within the promoter region and intron 1 (proNesFproNesR) (Table 3) , and the other was placed within promoter region and intron 6 (NesF-NesR) ( Table 3) .
LILRA2 splice site SNP in SLE and vasculitis K Mamegano et al Both PCRs were performed in 25 ml reaction mixtures containing 1 ml genomic DNA, 0.4 pM of each primer, 0.4 mM dNTPs, 2 mM MgCl 2 and 2.5 U LA Taq DNA polymerase (TAKARA, Otsu, Shiga, Japan), using a T-GRADIENT Thermocycler (Biometra GmbH, Göttingen, Germany) or a GeneAmp PCR system 9700 (PerkinElmer Applied Biosystems, Foster City, CA, USA). The amplification procedure consisted of initial denaturation at 96 1C for 5 min, 35 cycles of denaturation at 96 1C for 30 s, annealing at 60 1C for 30 s and extension at 72 1C for 2 or 3 min for each fragment, followed by the last extension at 72 1C for 7 or 10 min.
Each of the first PCR products was divided into several segments encompassing each exon, and was amplified using primers described in Table 3 (second PCR). Each second PCR and PCR for exon 7 were performed in 25 ml reaction mixtures containing 1 ml amplified PCR products, 0.4 pM each primer, 0.2 mM dNTPs, 2 mM MgCl 2 and 1 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems), using a T-GRADIENT Thermocycler or a GeneAmp PCR system 9700. The amplification condition consisted of initial denaturation at 96 1C for 10 min, 35 cycles of denaturation at 96 1C for 30 s, annealing at 64-66 1C for 30 s and extension at 72 1C for 30 s, followed by the last extension at 72 1C for 4 min. Fluorescence-based automated cycle sequencing of PCR products was performed using ABI 3100 sequencer (ABI PRISM; Applied Biosystems, Foster City, CA, USA) with the dye-terminator method, according to the manufacturer's instructions (BigDye ver3.1 Cycle Sequencing-Ready Reaction Kit).
Genotyping of LILRA2 rs3760856, rs28384501, rs28384502 was performed similarly, using nested PCR followed by direct sequencing. For the genotyping of rs2241524, a specific primer set LILRA2-SF and -SR was designed for a single-step PCR-direct sequencing.
Polymorphism screening, haplotype determination and genotyping of LILRA1 Polymorphisms of LILRA1 gene were screened using nested PCR followed by direct sequencing as in LILRA2. Genomic DNA samples from 16 healthy individuals were used for screening. The LILRA1 exon-intron structure was elucidated by comparing the LILRA1 mRNA sequence (NM_006863) with chromosome 19 contig sequences in the GenBank (AC009892) as well as in the Celera Discovery System (http://www.celera. com). Whereas LILRA1 exon 10 comprised 377 bp containing 258 bp 3 0 -untranslated region (UTR) according to GenBank NM_006863 sequence, it has elongated 3 0 -UTR sequence (1623 bp) in the Celera database. Therefore, we set the primers to cover whole LILRA1 mRNA sequence suggested by the Celera Discovery System. Primer set for nested first PCR was placed within the promoter region and within the intron 7 (LILRA1-sF1/LILRA1-sR1) (Table 4) , and the other primer set was placed within the intron 7 and at 3 0 -flanking region (LILRA1-sF2/LILRA1-sR2) ( Table 4) . Each of the first PCR products was divided into several segments for second PCR-direct sequencing (Table 4) . LILRA1 haplotypes were determined from the segregation pattern of the 31 Japanese families. In the Abbreviations: ex, exon; int, intron. These primers were designed according to the genomic DNA sequence of human LILRA2 (NCBI accession no. NC_000019). These primers were used for nested PCR primers except for LILRA2-SF and -SR, which were used to genotype rs2241524 by a single-step direct sequencing.
LILRA2 splice site SNP in SLE and vasculitis K Mamegano et al case-control studies, LILRA1 haplotypes were determined using a fragment containing tag SNPs on the assumption that these haplotypes are conserved in Japanese. The typing of haplotypes LILRA1.PC01 and LIL-RA1.PC02 was performed using the PCR/singlestranded conformation polymorphism (SSCP) method. A 516 bp fragment containing seven polymorphic sites (IVS1 þ 78G4A, IVS1 þ 163A4C, c.-44G4T, c.-37C4T, c.13G4C, c.18A4G and c.34A4G) was amplified using a primer set for direct sequencing (LILRA1-4F and LILRA1-4R) ( Table 4 ). The amplified DNA was analyzed using SSCP. One microliter of solution containing the PCR product was mixed with 7 ml of denaturing solution (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol FF). The mixtures were denatured at 96 1C for 5 min and immediately cooled on ice. One microliter of the mixtures was applied to polyacrylamide gel (acrylamide:bisacrylamide ¼ 49:1). Electrophoresis was carried out in 0.5 Â TBE (45 mM Tris-borate (pH8.0), 1 mM EDTA) under constant current of 20 mA per gel, 20 1C for 100 min in 10% polyacrylamide gel using a minigel electrophoresis apparatus with a constant temperature control system (90 Â 80 Â 1 mm, AE-8450, AB-1600 and AE-6370; ATTO, Tokyo, Japan). Singlestranded DNA fragments in the gel were visualized by silver staining (Daiichi Chemicals, Tokyo, Japan).
RT-PCR
Total RNA was extracted from peripheral blood mononuclear cells (PBMCs) using the PAXgene kit (Qiagen). First-strand cDNA was synthesized using Oligo(dT) primer (Promega, Madison, WI, USA) and ReverTra Ace (Toyobo, Osaka, Japan). To detect the difference between transcripts of GG and AA genotypes, RT-PCR was performed using primers designed within exon 6 and 7 (5 0 -CAGCAGAACCAGGCTGAATT-3 0 and 5 0 -GTGTAATCCTGGGGGTGTTG-3 0 ). One microliter of template cDNA solution was placed into 25 ml of reaction solution, and amplification was performed using AmpliTaq Gold DNA polymerase (Perkin-Elmer). The amplification conditions consisted of initial denaturation at 96 1C for 10 min, 35 cycles of denaturation at 96 1C for 30 s, annealing at 58 1C for 30 s and extension at 72 1C for 30 min, followed by the last extension at 72 1C for 2 min using GeneAmp PCR system 9700 (Perkin-Elmer Applied Biosystems). Detection of splicing isoform was performed using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Flow cytometric analysis
Surface expression intensity of LILRA2 in peripheral blood monocytes was examined in two healthy donors with LILRA2 rs2241524 G/G and two with A/A genotype by two-color flow cytometry, using rat These were designed according to the genomic DNA sequence containing human LILRA1 (GenBank accession no. AC009892).
LILRA2 splice site SNP in SLE and vasculitis K Mamegano et al anti-ILT1 mAb 135 14 and PE-conjugated goat F(ab 0 ) 2 fragment anti-rat IgG (H þ L) Ab (Beckman Coulter), as well as fluorescein-isothiocyanate-conjugated anti-CD14 mAb (Beckman Coulter).
Statistical analysis
The frequencies of the LILRA2 genotypes were compared between groups using the w 2 -test or Fischer's exact test. Statistical analyses were performed using StatView version 5.0 for Windows (Abacus Concepts Inc., Berkeley, CA, USA). LD analysis and estimation of haplotype frequencies were performed by the Estimation-Maximization algorithm using SNPAlyze program (DYNACOM, Mobara, Japan).
